Conferences - Results from #60

ASCO 2022: Olaparib Plus Abiraterone As First-Line Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: Pharmacokinetics Data From the PROpel Trial June 6, 2022

ASCO 2022: The Natural History and Genetics of Germ Cell Tumors - Discussion June 6, 2022

ASCO 2022: Reasons for Oncologist and Urologist Treatment Choice in Metastatic Castration-Sensitive Prostate Cancer: A Physician Survey Linked to Patient Chart Reviews in the United States June 6, 2022

ASCO 2022: Open-Label Study of Androgen Receptor Inhibition With Darolutamide + ADT Versus ADT in Men With mHSPC Using an External Control Arm (ARASEC) June 6, 2022

ASCO 2022: Efficacy and Safety of Relugolix in Men with Advanced Prostate Cancer Based on Baseline BMI: A Subgroup Analysis from the Randomized, Phase 3 HERO Study Versus Leuprolide June 6, 2022

ASCO 2022: PSMA PET Tumor-to-Salivary Glands Ratio (PSG Score) To Predict Response to Lu-177 PSMA Radioligand Therapy: An International Multicenter Retrospective Study June 6, 2022

ASCO 2022: Phase 3 VERACITY Clinical Study of Sabizabulin in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on an Androgen Receptor Targeting Agent June 6, 2022

ASCO 2022: Alkaline Phosphatase Decline and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in the REASSURE Study June 6, 2022

ASCO 2022: Piflufolastat F18-PET/CT in Patients With Prostate Cancer: An Analysis of OSPREY (Cohorts A and B) Standardized Uptake Value Results Stratified by PSA and Gleason Score June 6, 2022

ASCO 2022: Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials June 6, 2022

ASCO 2022: Late Relapses in Testicular Cancer: Results From a National Cohort June 5, 2022

ASCO 2022: Making Sense of the Intensified mHSPC Landscape - Discussion June 5, 2022

ASCO 2022: Defining Germline Genetics of Germ Cell Tumor: Implications for Genetic Testing and Clinical Management June 5, 2022

ASCO 2022: A Phase 3 Trial of SHR3680 Versus Bicalutamide in Combination With ADT in Patients With High-Volume mHSPC June 5, 2022

ASCO 2022: Assessing Intermediate Clinical Endpoints As Potential Surrogates for Overall Survival in Men With mHSPC June 5, 2022

ASCO 2022: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP June 5, 2022

ASCO 2022: Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) June 5, 2022

ASCO 2022: Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). June 5, 2022

ASCO 2022: Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in mHSPC June 5, 2022

ASCO 2022: [177Lu]Lu-PSMA-617 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial June 5, 2022

Page 4 of 472

email news signup